The bill directs the Secretary of Defense to develop and deliver, within one year of enactment, a comprehensive strategy on the national security implications of emerging biotechnologies. The strategy must be produced in coordination with the Under Secretary of Defense for Research and Engineering and the Under Secretary of Defense for Acquisition and Sustainment, and submitted to the Armed Services Committees.
This is a planning and policy mandate rather than an authorization of specific programs or funding. Still, the bill asks the Department to map concrete levers — from expanding commercial biomanufacturing capacity to altering acquisition approaches and working with NATO partners — that could change how the Department buys, tests, and coordinates biotechnology-reliant capabilities.
At a Glance
What It Does
The bill requires the Secretary of Defense, working with USD(R&E) and USD(A&S), to produce a written strategy within one year identifying how emerging biotechnology will affect defense and how DoD should respond across procurement, standards, testing, and partnerships. It lists a set of analytical and programmatic topics the strategy must cover.
Who It Affects
Acquisition and research offices inside DoD, commercial biomanufacturers and startups, defense contractors that supply biologically enabled products, and allied partners (particularly NATO members) who could be invited into pooled purchasing and joint research efforts. Regulators and standards bodies will also be implicated if the Department pursues a regulatory-science program.
Why It Matters
The requirement converts broad concern about biotech into a single DoD roadmap that could reshape acquisition approaches, market signals for industry, and international cooperation. That roadmap will influence procurement planning, standards updates, and whether DoD invests in tools to make biotechnology more predictable and interoperable for military use.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill compels DoD to stop treating emerging biotechnology as an abstract risk and instead produce an operational blueprint. By asking the Secretary to coordinate with the offices that set research priorities and run acquisitions, the statute forces the strategy to bridge lab priorities with buying authorities — a gap that often slows adoption of new technologies.
The one‑year deadline and the requirement to deliver the strategy to the Armed Services Committees create a discrete accountability point for DoD leadership.
The statute guides the Department to think across four practical domains: supply and industrial capacity, acquisition and standards, analytic planning (wargames and net assessments), and regulatory/measurement tools. For supply, the Department must describe how it would grow a network of commercial biomanufacturing facilities for defense‑critical products; this is about reducing single‑source risk and creating surge capacity.
On acquisition, DoD must evaluate how to update military specifications so biological substitutes can be judged acceptable and interoperable with legacy systems, and how to use advance market commitments or offtake agreements to reduce investment risk for suppliers.On planning and threat assessment, the Department must show how biotechnology fits into exercise design and net assessment so decisionmakers can model operational impacts. The statute also asks DoD to evaluate a “grand challenge” approach aimed at making biotechnology more predictably engineerable — the bill requires a benefits‑and‑costs analysis and an implementation plan for such challenges.
Finally, the bill asks DoD to build a regulatory science and technology function, including digital infrastructure and biometrology tools, and to outline how it would coordinate procurement and R&D aggregation with NATO partners to leverage allied market power and joint research capabilities. Together those elements are designed to turn strategic intent into acquisition signals, measurement tools, and multinational coordination frameworks.
The Five Things You Need to Know
The bill requires the Secretary of Defense to submit a written biotechnology strategy to the House and Senate Armed Services Committees within one year of enactment.
The Secretary must prepare the strategy in coordination with the Under Secretary of Defense for Research and Engineering and the Under Secretary of Defense for Acquisition and Sustainment.
The strategy must evaluate using advance market commitments and offtake agreements as procurement tools to guarantee demand for biotechnology products with defense applications.
The Department must assess the benefits, costs, and an implementation plan for a research ‘grand challenge’ (or series of challenges) focused on making biotechnology predictably engineerable.
The strategy must include creation of a Departmental biotechnology regulation science and technology program, including digital infrastructure to simplify regulation and development of biometrology tools.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
A single line that names the statute the "Defense Biotechnology Strategy Act." This is purely nominal and does not change any authorities or appropriations; it simply frames the document that follows.
Strategy requirement and reporting line
This subsection imposes the central obligation: within one year the Secretary must deliver a strategy on the national security implications of emerging biotechnologies. It mandates coordination with USD(R&E) and USD(A&S) and delivery to the House and Senate Armed Services Committees. Practically, this pushes the strategy to be both technically informed and acquisition‑aware; it forces collaboration between research offices and the component responsible for procurement.
Expanding commercial biomanufacturing for defense needs
The Department must describe how it would develop and expand a network of commercial biomanufacturing facilities for products critical to defense. That requires mapping current commercial capacity, identifying surge and geographic resilience gaps, and proposing mechanisms (e.g., contracting models, incentives, or partnerships) to grow capacity without creating permanent, single‑use government facilities.
Updating military specifications and using advance market commitments
DoD must review military specifications to allow biotechnology‑based substitutes and recommend how to implement advance market commitments and offtake agreements. Operationally, this implicates standards development, testing protocols, acceptance criteria, and procurement vehicles that reduce market risk for suppliers while preserving oversight and quality assurance in defense systems.
Wargaming, research grand challenges, and a regulatory science program
The bill directs DoD to integrate biotechnology into exercises and net assessments so planners can see operational effects, to analyze whether a research grand challenge could make biotech more predictable (including benefits and costs), and to build a regulatory science and technology program with digital infrastructure and biometrology tools. Together these provisions push DoD to invest in measurement, standards, and training that would make biological capabilities tractable for military planning and acquisition.
NATO aggregation and international research coordination
The Department must propose how it could encourage NATO members to aggregate demand and pool purchasing power for biotechnology products, and how to coordinate multinational biotechnology research initiatives. This requires addressing interoperability, pooled contracting mechanisms, information sharing, and reconciling differing regulatory regimes among allies.
This bill is one of many.
Codify tracks hundreds of bills on Defense across all five countries.
Explore Defense in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- U.S. military planners and combatant commanders — clearer analytical tools and updated specs will let planners consider biotechnology in operational planning and logistics, improving readiness for biological supply‑chain disruptions.
- Commercial biomanufacturers and biotech startups — the strategy's emphasis on advance market commitments, offtake agreements, and an expanded commercial manufacturing network promises stronger demand signals and procurement pathways for companies willing to meet defense requirements.
- NATO member defenses — if DoD follows through on pooled purchasing and coordinated R&D, smaller allies could gain access to biotech capabilities and shared surge capacity they could not build alone.
- DoD research and standards communities — a regulatory science program and investment in biometrology will create tools and data that make research outcomes more comparable and actionable for acquisition.
- Defense acquisition professionals — updated specifications and clearer acceptance criteria reduce ambiguity when evaluating biotech alternatives, simplifying their job of integrating new suppliers and technologies.
Who Bears the Cost
- Department of Defense budgets and program offices — preparing and implementing the strategy, staffing a regulatory science program, and seeding biomanufacturing networks will require funding that must be absorbed into existing budgets or requested from Congress.
- Acquisition and contracting offices — using advance market commitments and offtake agreements will require new contracting approaches, legal work, and oversight capacity, increasing workload and procurement complexity in the near term.
- Small biotech firms with limited compliance resources — participating in defense procurement and meeting military specifications or biometrology standards could raise entry costs even as demand increases.
- Allied governments and NATO bodies — pooled purchasing and harmonized research require political and administrative investment from partner nations and may impose obligations on their procurement systems.
- Standards and metrology organizations — producing and maintaining biometrology tools and digital infrastructure will require long‑term commitment and coordination across public and private institutions.
Key Issues
The Core Tension
The central dilemma is between speed and control: DoD wants to accelerate adoption of biotechnology (and use procurement power to shape markets), but doing so risks outpacing regulatory safeguards, international agreements, and measurement standards; the bill asks DoD to hasten market and capability development while also ensuring reliability, interoperability, and allied trust — goals that can push in opposite directions.
The bill is a planning mandate that asks DoD to knit together research, acquisition, and international cooperation, but it leaves several implementation questions open. First, it does not appropriate funding or specify authorities for the actions it requests.
Building commercial biomanufacturing networks, running grand challenges, or standing up a regulatory science program will require money and possibly new contracting authorities or interagency agreements. Without clear resourcing, the strategy risks becoming a list of desirable outcomes without executable plans.
Second, the bill raises governance tensions: encouraging commercial engagement and pooled NATO purchasing will encounter export-control, intellectual property, and regulatory divergence issues across allies. Harmonizing standards and sharing sensitive capabilities with partners poses legal and political hurdles that the strategy must confront.
The request for a regulatory science program and biometrology tools also surfaces a technical challenge: the field lacks mature, widely accepted measurements for many biological processes, so the Department's proposals will need realistic timelines and staged milestones.
Finally, the grand challenge concept — to make biotechnology ‘‘predictably engineerable’’ — is attractive but technically ambitious. The strategy must weigh whether such a program would accelerate useful, militarily relevant advances or divert resources from more incremental, operationally immediate measures like supply‑chain redundancy and standards harmonization.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.